Reducing Treatment Burden and Improving Outcomes in Neovascular Age-Related Macular Degeneration (nAMD): What Managed Care Needs to Know about Emerging Therapies

 

A continuing medical education activity sponsored by NAMCP and AAMCN 

This webinar series will provide critical updates on the advances in immunotherapies, including
how to translate the most recent data into clinical and administrative practice.

These are archives of live webinars held between November 13 to November 19, 2019.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

Each session has its own specific valid dates


This series is supported by an educational grant from Novartis Pharmaceuticals Corporation.

 

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Age-related macular degeneration (AMD) is a leading cause of severe vision loss among people aged 50 years and older. It is estimated that nearly 3 million individuals in the US will develop AMD by 2020 and that the prevalence will continue to increase due to the aging population. Neovascular, or "wet" AMD imposes a high burden on patients, eye care providers and payers alike, as optimal visual outcomes have been contingent on regular, ongoing treatment. Fortunately for patients with nAMD, new treatments have arrived or are on the horizon. This webinar series will feature strategies to reduce treatment burden and improve outcomes as experts will discuss the current burden of treatment, evaluate new dosing and administration schedules, as well as review the safety and efficacy of therapies in late-stage development. 


Reducing Treatment Burden with Emerging Therapies in the Management of Neovascular Age-Related Macular Degeneration (nAMD): Comparing Recent Clinical Trial Outcomes

  1. Assess the burden associated with the conventional use of anti-VEGF agents in the treatment of neovascular age-related macular degeneration (nAMD)
  2. Identify early signs of nAMD based on recommended tests
  3. Analyze new evidence pertaining to the safety and efficacy of new and emerging therapies in the management of nAMD
  4. Discuss new dosing and administration schedules for the treatment of nAMD that may reduce injection frequency while maintaining visual acuity
  5. Differentiate new and emerging agents and modalities for nAMD, based on clinical profile, mechanism of action, pharmacology, dosing, and delivery, as appropriate
       Physician, Nursing and CMCN credits valid to December 1, 2021

Improving Quality of Life in Neovascular Age-Related Macular Degeneration (nAMD): Evaluating New Dosing Options and Mechanisms for Delivery of Agents

  1. Assess challenges to patient adherence, dosing and quality of life in nAMD management
  2. Examine dosing schedules for new and emerging therapies and how they could change patient management and treatment frequency
  3. Analyze treatment durability associated with new and emerging agents in the management of nAMD
  4. Discuss strategies to monitor and manage adverse events associated with emerging agents in nAMD in order to improve patient adherence and quality of life
  5. Review evolving individualized treatment plans based on evidence-based monitoring strategies for patients with nAMD
       Physician, Nursing and CMCN credits valid to December 1, 2021

What Managed Care Needs to Know about Emerging Therapies and Treatment Frequency in Management of Neovascular Age-Related Macular Degeneration (nAMD)

  1. Discuss current economic and logistic barriers to appropriate nAMD therapy and lessening treatment burden in the managed care setting
  2. Characterize the disease burden of nAMD in the managed care setting as determined by treatment frequency, visual acuity and other measurements
  3. Assess the managed care considerations of new and emerging therapies in nAMD by reviewing recent updates and clinical data
  4. Apply methods to enable optimal cost management of new and emerging therapies to be realized by multiple nAMD stakeholders, including managed care organizations
  5. Analyze utilization management and benefit design strategies for emerging nAMD therapies to enhance clinical and economic outcomes for patients with nAMD
       Physician, Nursing and CMCN credits valid to December 1, 2021